TUCSON, Ariz., April 23, 2013 — The Muscular Dystrophy Association (MDA) announced today that Cytokinetics Inc. is a “silver” sponsor of the 2013 MDA Conference, “Therapy Development for Neuromuscular Diseases: Translating Hope Into Promise," currently under way in Washington, D.C., and running through April 24. The conference is highlighting the rapid evolution of neuromuscular disease research over the last five.
Today, Jinsy Andrews, M.D., director of clinical research and development at Cytokinetics, will give a presentation titled, “Tirasemtiv (CK-2017357): A Selective Fast Skeletal Muscle Troponin Activator for the Potential Treatment of ALS,” during the meeting’s Clinical Trials session. Dr. Andrews also presented a poster with the same title during the Poster Session Monday evening.
ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease) is one of the more than 40 neuromuscular diseases covered by MDA.
"Progress has been so rapid in biotech research that we now have many promising new paths for treatment development,” said MDA Vice President of Research Jane Larkindale. "Our conference covers a broad range of innovative projects from early-stage therapeutic targets to clinical trial results. We welcome and appreciate support for the conference from Cytokinetics. MDA has been funding muscle disease research formore than 60 years, and the progress that Cytokinetics is making brings new hope to MDA families.”
More than 500 scientists, many of whom are at the vanguard of neuromuscular disease research, are attending the MDA conference and presenting their newest findings relating to Duchenne muscular dystrophy, spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and additional neuromuscular diseases.
“Cytokinetics is pleased to provide sponsorship to this conference. It has brought together hundreds of professionals dedicated to advancing the field of neuromuscular disease research and inspires innovation like that which contributed to the discovery and development of tirasemtiv,” Andrews stated. “MDA plays an important role in organizing forums such as this one to share progress toward potential treatments for serious neuromuscular diseases.”
Fueled by rapidly evolving biotechnology practices, an unprecedented number of new potential disease therapies have been developed. In addition to the academic scientists who are attending the meeting, MDA is bringing together professionals from government, industry and the nonprofit sector to join the discussion about novel therapy development for neuromuscular disorders.
Conference co-chairs are: C. Frank Bennett, senior vice president for research at Isis Pharmaceuticals; and Eric Hoffman, Director of the Research Center for Genetic Medicine at Children's National Medical Center in Washington, D.C.
MDA is the nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, ALS and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education.
In addition to funding more than 250 research projects worldwide, MDA maintains a national network of 200 medical clinics; facilitates hundreds of support groups for families affected by neuromuscular diseases; and provides local summer camp opportunities for thousands of youngsters living with progressive muscle diseases.